Patients

Access to innovative medicines

Since our founding, we have valued pioneering approaches to advancing transformational medicines for diseases with significant unmet medical needs. Our commitment to improving the lives of people around the world is reflected in our innovative research, product development and patient access to our innovative medicines.

That is why we value continued improvement in our research, development, and access approaches, in an unwavering focus on outcomes with the greatest value to patients. It is why we embrace change and support disruptive innovation, and aim to build a culture of responsible innovation throughout the entire medicine lifecycle and are committed to enable the safe and appropriate use of our medicines as they are prescribed by physicians and used by patients in the medical practice.

From lab to patients

We focus our development efforts on areas where we have deep expertise and map out the critical path towards market with the goal of reducing the time it takes to bring new medicines to the patients who need them.

Pioneering for patients, with patients

At every stage of the patient journey, we aim to pioneer for patients by working in close partnership with patients and patient organizations, starting with the design of our clinical studies.

We therefore co-developed our Patient Partnership Charter in 2021 with the patient community to set our commitment to engage with patients. Using the Charter as a guideline we defined our roadmap to:

• Strengthen our relationships with academia, patient groups, and industry partners;
• Include patient and investigational site expectations into the design of late phase clinical trials with the aim of making participation easier and more rewarding;
• Identify measurable performance indicators; and
• Assess our performance during clinical development as well as after.